The Patent Finder
PR

Prognomiq, Inc.

First filing 2022
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Six patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2041. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2041
Next term end
4
Patent families

When these terms end

Each bar runs from grant to computed term end. 2023 to 2044.
US 11,664,092 Lung Biomarkers and Methods of Use Thereof Jan 27, 2041
US 12,087,405 Methods of Processing a Biofluid Sample Jan 27, 2041
US 12,334,190 Multi-Omic Assessment Using Proteins and Nucleic Acids no later than Mar 30, 2042
US 12,007,397 Enhanced Detection and Quantitation of Biomolecules Sep 12, 2042
US 12,504,432 Enhanced Detection and Quantitation of Biomolecules Sep 12, 2042
US 12,387,508 Direct Classification of Raw Biomolecule Measurement Data Jan 5, 2044
202720312035203920432044
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
10 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for Lung Biomarkers and Methods of Use Thereof (US 11,664,092) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 3 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 6 of 6

PatentTitleStatusExpiresConfidence
US 11,664,092Lung Biomarkers and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,087,405Methods of Processing a Biofluid Sample
In force
 · High confidence
In forceHigh confidence
US 12,334,190Multi-Omic Assessment Using Proteins and Nucleic Acids
In force
 · Medium confidence
In forceMedium confidence
US 12,007,397Enhanced Detection and Quantitation of Biomolecules
In force
 · High confidence
In forceHigh confidence
US 12,504,432Enhanced Detection and Quantitation of Biomolecules
In force
 · High confidence
In forceHigh confidence
US 12,387,508Direct Classification of Raw Biomolecule Measurement Data
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 6: 10 applications pending · 6 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited